1. Scrip
  2. >>New Products

Five-Plus-Five Equals A Focus On Execution At Lilly In 2023

Approvals Near For Four New Drugs, One New Indication

 
• By Mandy Jackson

Executives told Scrip the company is ready to move five programs into Phase III and launch five products this year, including an obesity indication for Mounjaro, but one drug has since received a CRL.

Office building at Lilly's Indianapolis HQ
Lilly's donanemab setback still could result in a win with positive Phase III data in Q2 • Source: Shutterstock

The theme for Eli Lilly and Company this year is “five-plus-five” as it prepares for five launches – four new medicines and a new obesity indication for diabetes therapy Mounjaro (tirzepatide) – and takes five candidates into Phase III trials. The company will have to remain focused on execution across multiple therapeutic areas, but chief scientific and medical officer Daniel Skovronsky and president of Lilly Diabetes Michael Mason said they believe their teams are up to the task, and that the existing experience in diabetes provides a strong base.

However, the week after Scrip spoke with Skovronsky, who is also president of Lilly Research Laboratories, and Mason at the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Atai/Beckley Merger Comes At A Transformative Time For Psychedelics

 
• By Kevin Grogan

All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

More from Scrip

Santen Sees Potential In Myopia Market After Ryjunea Approval

 
• By Kevin Grogan

The low-dose atropine eye drop slowed the progression of pediatric myopia by 30%.

Will Pfizer Walk Away From Arvinas After PROTAC Disappointment?

 
• By Andrew McConaghie

Arvinas and Pfizer have just filed the potential first-in-class protein degrader vepdegestrant, but its diminished commercial prospects after mixed Phase III data mean Pfizer could exit.

Executives On The Move: Three New CEOs And CFOs Among This Week’s Changes

Recent moves in the industry include changes at the top at Mitsubishi Tanabe Pharma and MC2 Therapeutics, plus MindMed acquires chief financial officer from Longboard Pharma.